Impact of rituximab in Mexican patients with Multiple Sclerosis–A single-center retrospective study

•Treatment for people with Multiple Sclerosis (MS) is often expensive and difficult to access in lower and middle countries.•Rituximab is commonly used worldwide given its lower costs and availability.•Previous phase-I and phase-II clinical trials have reported reduction in relapses and MRI activity...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2022-02, Vol.58, p.103485-103485, Article 103485
Hauptverfasser:	Bribiesca-Contreras, Elisa, García-Estrada, Christian, Gómez-Figueroa, Enrique, Zertuche-Ortuño, Lizeth, Rodríguez-Rivas, Roberto, Marcín-Sierra, Mariana, Delgado-Niño, Maryori, Rivas-Alonso, Verónica, Corona-Vázquez, Teresita, Flores-Rivera, José
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use ARR: anual relapsed rate EDSS: expanded dissability status scale Humans Immunologic Factors - adverse effects Multiple Sclerosis - chemically induced Multiple Sclerosis - diagnostic imaging Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy PI: progression index PPMS: primary progressive Multiple Sclerosis Retrospective Studies Rituximab - adverse effects RMS: relpasing Multiple Sclerosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!